Study of Iberdomide in People With Multiple Myeloma Who Have Had an Autologous Hematopoietic Stem Cell Transplant (AHCT)
Summary
Third Opinion Trial Synopsis:
This study wants to find out if a drug called iberdomide is safe and works well as a treatment for people with a cancer called Multiple Myeloma. These people have already had a certain kind of treatment called Autologous Hematopoietic Stem Cell Transplant and have taken another drug called lenalidomide. The researchers want to know if iberdomide could be another option for them to keep their cancer under control.
This study wants to find out if a drug called iberdomide is safe and works well as a treatment for people with a cancer called Multiple Myeloma. These people have already had a certain kind of treatment called Autologous Hematopoietic Stem Cell Transplant and have taken another drug called lenalidomide. The researchers want to know if iberdomide could be another option for them to keep their cancer under control.
*Third Opinion AI Generated Synopsis
Trial Summary
The purpose of this study is to see if iberdomide is a safe and effective maintenance therapy option for people with Multiple Myeloma (MM) who have had an Autologous Hematopoietic Stem Cell Transplant (AHCT) and have already had lenalidomide as maintenance therapy. Patients will receive iberdomide treatment beyond 12 months if they continue to derive benefit from the treatment and will continue until progression of disease or unacceptable toxicity. Follow-up will be as per standard of care for a patient on maintenance therapy, and patients will not require additional research samples.
The purpose of this study is to see if iberdomide is a safe and effective maintenance therapy option for people with Multiple Myeloma (MM) who have had an Autologous Hematopoietic Stem Cell Transplant (AHCT) and have already had lenalidomide as maintenance therapy. Patients will receive iberdomide treatment beyond 12 months if they continue to derive benefit from the treatment and will continue until progression of disease or unacceptable toxicity. Follow-up will be as per standard of care for a patient on maintenance therapy, and patients will not require additional research samples.
Locations & Contact
Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts: